CORRESP

Kura Oncology, Inc.

11119 N. Torrey Pines Road

Suite 125

La Jolla, CA 92037

(858) 500-8800

November 2, 2015

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Alla Berenshteyn

 

Re:    Kura Oncology, Inc.
   Registration Statement on Form S-1
   Filed: October 20, 2015
   File No. 333-207534

Ladies and Gentlemen:

Kura Oncology, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective at 4:00 p.m. Eastern Time on Wednesday, November 4, 2015, or as soon thereafter as is practicable. The Registrant also hereby requests a copy of the written order verifying the effective date.

In connection with this request, the Registrant hereby acknowledges that:

 

    should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 

    the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

    the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.


Sincerely,

KURA ONCOLOGY, INC.

 

By:  

/s/ Heidi Henson

  Heidi Henson
  Chief Financial Officer
cc:   Charles J. Bair, Cooley LLP
  James Pennington, Cooley LLP